Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE)
Selleck Chemicals
SKU:D4061-1MG
Couldn't load pickup availability
Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an antibody-drug conjugate (ADC) targeting GPC3 (glypican-3).
Product overview
It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and is relevant to research on hepatocellular carcinoma (HCC). The product background identifies the antibody component, target antigen and payload or linker architecture where these details are supplied. This ADC context supports comparison of antigen recognition, payload conjugation and cellular uptake behavior in controlled assay systems, especially when researchers need to distinguish conjugated biologics from unconjugated antibodies or standalone small molecules.
Laboratory context
The listed workflow context supports binding and uptake-oriented laboratory studies where a defined antibody component, cellular target and conjugated payload are relevant to assay planning, including cell-surface binding, cell-uptake and protein-binding experiments, within oncology and metabolism research.
- Research Area:
- Oncology • Metabolism
- Application:
- Cell Surface Binding • Cell Uptake Studies • Protein Binding
- Formulation:
- 100 mM Pro-Ac, 20mM Arg, pH5.0
- CAS No.:
- 1365267-33-9
- Molecular Weight:
- 145.58
- Storage Temperature:
- -20°C
For Research Use Only. Not intended for diagnostic or therapeutic use.
Products may be subject to intellectual property rights.
The purchase of this product does not grant any license for commercial use, manufacturing, or clinical applications. The user is responsible for ensuring compliance with applicable laws and third-party rights.